Micafungin Hikma
Echinocandin antifungal — powder for concentrate for solution for infusion
Quick Facts About Micafungin Hikma
Key Takeaways About Micafungin Hikma
- Hospital-only antifungal: Micafungin Hikma is given by slow intravenous infusion over approximately 1 hour and must be administered by healthcare professionals
- First-line for invasive candidiasis: International guidelines (IDSA, ESCMID) recommend echinocandins like micafungin as first-line treatment for invasive Candida infections
- Approved for children and neonates: Micafungin can be used in paediatric patients including newborns, with weight-based dosing
- Monitor liver function: Hepatotoxicity has been reported; liver function tests should be monitored before and during treatment
- Selective mechanism of action: Targets fungal cell wall synthesis (1,3-beta-D-glucan) which does not exist in human cells, resulting in good tolerability
What Is Micafungin Hikma and What Is It Used For?
Micafungin Hikma is an echinocandin antifungal medicine containing the active substance micafungin. It is used to treat serious fungal infections caused by Candida species, including invasive candidiasis (candidaemia), oesophageal candidiasis, and for prophylaxis in immunocompromised patients at high risk of developing Candida infections.
Micafungin belongs to the echinocandin class of antifungal agents, which are considered among the most important advances in antifungal therapy over the past two decades. Unlike azole antifungals (such as fluconazole or voriconazole) which target the fungal cell membrane, micafungin targets the fungal cell wall by inhibiting the enzyme 1,3-beta-D-glucan synthase. This enzyme is responsible for producing 1,3-beta-D-glucan, a critical structural polysaccharide found exclusively in fungal cell walls. Because mammalian cells lack this component entirely, micafungin demonstrates excellent selectivity and a favourable safety profile.
The drug is manufactured by Hikma Pharmaceuticals as a powder for concentrate for solution for infusion, available in 50 mg vials. Once reconstituted and diluted, it is administered as a slow intravenous infusion over approximately one hour. Micafungin cannot be taken orally because, like other echinocandins, it has very low oral bioavailability due to its large molecular size and poor gastrointestinal absorption.
Approved indications
Micafungin Hikma is approved for the following indications in adults, adolescents, children, and neonates:
- Treatment of invasive candidiasis: Including candidaemia (Candida bloodstream infection), acute disseminated candidiasis, Candida peritonitis, and Candida abscess formation. Invasive candidiasis is a life-threatening condition with mortality rates of 30–40% even with appropriate antifungal therapy, making timely and effective treatment essential.
- Treatment of oesophageal candidiasis: In patients for whom intravenous therapy is appropriate, particularly those who have failed or are intolerant to other antifungal agents.
- Prophylaxis of Candida infections: In patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) or those who are expected to have neutropenia (absolute neutrophil count <500 cells/μL) for 10 or more days. Prevention of invasive fungal infections in these highly immunocompromised populations is critical, as treatment of established infections carries significantly higher morbidity and mortality.
How micafungin works
Micafungin is a semi-synthetic lipopeptide compound synthesised from a fermentation product of the fungus Coleophoma empetri. Its mechanism of action is highly specific: it non-competitively inhibits the enzyme 1,3-beta-D-glucan synthase. This enzyme catalyses the formation of 1,3-beta-D-glucan, a glucose polymer that is essential for maintaining the structural integrity and osmotic stability of the fungal cell wall.
When 1,3-beta-D-glucan synthesis is inhibited, the fungal cell wall becomes weakened and structurally compromised, leading to osmotic instability and ultimately fungal cell lysis and death. This mechanism is fungicidal against most Candida species (meaning it kills the fungi) and fungistatic against Aspergillus species (meaning it prevents their growth). The clinical spectrum of activity includes C. albicans, C. glabrata, C. tropicalis, C. krusei, and C. parapsilosis, though minimum inhibitory concentrations (MICs) are generally higher for C. parapsilosis.
International guidelines from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend echinocandins as first-line empirical therapy for invasive candidiasis. This recommendation is based on their broad-spectrum anti-Candida activity, favourable safety profile, minimal drug interactions compared to azoles, and efficacy against fluconazole-resistant species such as C. glabrata and C. krusei.
What Should You Know Before Receiving Micafungin Hikma?
Before receiving Micafungin Hikma, inform your doctor about any allergies to antifungal medicines, liver disease, kidney problems, or if you are pregnant or breastfeeding. Micafungin is contraindicated in patients with known hypersensitivity to micafungin, any other echinocandin, or any of its excipients.
As Micafungin Hikma is administered in a hospital setting by healthcare professionals, your treating physician will assess whether this medicine is appropriate for you. However, it is important that you provide complete information about your medical history and current medications so that potential risks can be evaluated and managed.
Contraindications
Micafungin Hikma must not be used if you have a known hypersensitivity (allergy) to micafungin sodium, to any other echinocandin antifungal, or to any of the excipients contained in the formulation. Serious hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, have been reported rarely during micafungin administration. If such a reaction occurs, the infusion must be discontinued immediately and appropriate emergency treatment initiated.
Cross-sensitivity between echinocandins has not been well established in clinical studies. However, caution is warranted when switching between echinocandin agents (such as caspofungin or anidulafungin) in patients who have previously experienced hypersensitivity to one member of this class. Your doctor will carefully weigh the risks and benefits before prescribing micafungin if you have a history of allergic reactions to related medicines.
Warnings and precautions
Several important warnings and precautions apply to the use of micafungin:
- Hepatotoxicity: Cases of serious hepatic dysfunction, hepatitis, and hepatic failure have been reported in patients receiving micafungin. Some patients had pre-existing serious conditions and were receiving other potentially hepatotoxic medications concurrently. Elevations in liver enzymes (ALT, AST, alkaline phosphatase, and total bilirubin) occur commonly during treatment. Your doctor should monitor your liver function tests before starting micafungin and at regular intervals during therapy. If clinically significant liver enzyme elevations occur, the benefit-risk of continuing treatment should be reassessed.
- Haemolysis: Rare cases of haemolytic anaemia (destruction of red blood cells) and haemoglobinuria have been reported. If signs of haemolysis develop during treatment, your doctor should carefully evaluate whether to continue micafungin therapy.
- Renal effects: Elevations in blood urea nitrogen (BUN) and serum creatinine have been observed. Worsening of pre-existing renal insufficiency has been reported. Renal function should be monitored during treatment.
- Infusion-related reactions: Histamine-mediated symptoms including rash, pruritus (itching), facial swelling, and vasodilatation (flushing) have been reported during micafungin infusion. Slowing the infusion rate may reduce the incidence of these reactions. In more severe cases, the infusion may need to be stopped.
- Development of resistance: As with all antimicrobial agents, prolonged use of micafungin may lead to selection of resistant fungal organisms. If breakthrough fungal infection occurs during micafungin therapy, appropriate susceptibility testing and alternative antifungal treatment should be considered.
Pregnancy and breastfeeding
There are no adequate and well-controlled studies of micafungin use in pregnant women. Animal reproduction studies have demonstrated adverse effects on the developing foetus, including visceral and skeletal malformations in rabbits at doses similar to the clinical exposure. Micafungin should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment with micafungin.
It is not known whether micafungin is excreted in human breast milk. Animal data show that micafungin is present in the milk of lactating rats. A decision must be made whether to discontinue breastfeeding or to discontinue micafungin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If you are breastfeeding or planning to breastfeed, discuss this with your doctor before treatment begins.
Tell your doctor immediately if you experience any of the following during or after micafungin infusion: skin rash or hives, difficulty breathing, swelling of the face or throat, severe itching, chest tightness, dizziness, or a sudden drop in blood pressure. These may be signs of a serious allergic reaction requiring immediate medical attention.
How Does Micafungin Hikma Interact with Other Drugs?
Micafungin has relatively few clinically significant drug interactions compared to azole antifungals. However, it can increase plasma levels of sirolimus, nifedipine, and itraconazole. Co-administration with amphotericin B may increase the risk of renal toxicity. Always inform your doctor of all medications you are taking.
One of the significant clinical advantages of echinocandins, including micafungin, is their relatively limited drug interaction profile. Unlike azole antifungals, micafungin is not a significant substrate, inducer, or inhibitor of cytochrome P450 enzymes. It is primarily metabolised by arylsulphatase and catechol-O-methyltransferase, pathways that are less commonly involved in drug metabolism. Nonetheless, some clinically relevant interactions have been identified and should be considered when micafungin is used concomitantly with other medications.
| Interacting Drug | Effect | Severity | Clinical Recommendation |
|---|---|---|---|
| Sirolimus | Micafungin increases sirolimus AUC by approximately 21% | Moderate | Monitor sirolimus levels; dose adjustment may be needed |
| Nifedipine | Micafungin increases nifedipine AUC by approximately 18% | Moderate | Monitor for nifedipine toxicity (hypotension, oedema) |
| Itraconazole | Micafungin increases itraconazole AUC by approximately 22% | Moderate | Monitor for itraconazole toxicity; consider dose adjustment |
| Amphotericin B (deoxycholate) | Potential additive nephrotoxicity; no pharmacokinetic interaction | Major | Avoid combination if possible; monitor renal function closely |
| Ciclosporin | No clinically significant pharmacokinetic interaction identified | Low | No dose adjustment required; routine monitoring |
| Tacrolimus | No clinically significant pharmacokinetic interaction identified | Low | No dose adjustment required; routine monitoring |
| Mycophenolate mofetil | No clinically significant interaction | Low | No dose adjustment required |
Major interactions
The most clinically important interaction to be aware of is the combination of micafungin with amphotericin B deoxycholate. While no pharmacokinetic interaction occurs (meaning neither drug affects the blood levels of the other), the combination carries an increased risk of nephrotoxicity (kidney damage). Both agents can independently cause renal impairment, and together the effect may be additive. This combination should generally be avoided; if it is considered necessary, close monitoring of renal function (serum creatinine, BUN, urine output) is essential.
Minor interactions
Micafungin has been shown to cause modest increases in the plasma exposure of several drugs. The increases in AUC (area under the curve) for sirolimus (approximately 21%), nifedipine (approximately 18%), and itraconazole (approximately 22%) are generally considered to be of moderate clinical significance. For most patients, these changes may not require dose adjustment, but enhanced monitoring for signs of toxicity from the co-administered drug is advisable. In the case of sirolimus, which has a narrow therapeutic index, therapeutic drug monitoring with potential dose reduction is recommended.
Importantly, micafungin does not interact significantly with several commonly used immunosuppressants including ciclosporin, tacrolimus, and mycophenolate mofetil. This is clinically advantageous in transplant recipients, who are at high risk for invasive fungal infections and frequently receive these immunosuppressive medications. The lack of significant interactions with these agents makes micafungin a particularly suitable choice in the transplant setting.
What Is the Correct Dosage of Micafungin Hikma?
Micafungin Hikma dosing depends on the indication and patient weight. For invasive candidiasis in adults, the recommended dose is 100 mg once daily (200 mg daily if inadequate response). For prophylaxis, the dose is 50 mg once daily. Children weighing less than 40 kg receive higher doses per kilogram of body weight.
Micafungin Hikma should be initiated by a physician experienced in the management of invasive fungal infections. All doses are administered as a single daily intravenous infusion over approximately one hour. The drug should not be administered as a bolus injection, as this has not been studied and may increase the risk of adverse reactions. Treatment duration should be determined by clinical and microbiological response; in general, antifungal treatment should continue for at least one week after clinical symptoms have resolved and cultures have become negative.
Adults
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Invasive candidiasis | 100 mg/day (may increase to 200 mg/day) | Minimum 14 days after last positive culture | Increase dose if clinical response inadequate |
| Oesophageal candidiasis | 150 mg/day | Minimum 7 days after symptom resolution | For patients requiring IV therapy |
| Prophylaxis of Candida infections | 50 mg/day | Until neutrophil recovery or no longer at risk | Continue for at least 7 days after ANC >500 |
Children
Micafungin is one of the few antifungal agents approved for use in neonates (less than 4 weeks old), infants, and children. Paediatric dosing is weight-based and generally results in higher per-kilogram doses compared to adults, reflecting the increased clearance of micafungin observed in younger patients. For children weighing 40 kg or more, adult dosing recommendations apply.
| Indication | Dose | Notes |
|---|---|---|
| Invasive candidiasis | 2 mg/kg/day (may increase to 4 mg/kg/day) | Increase if clinical response inadequate |
| Oesophageal candidiasis | 3 mg/kg/day | For children requiring IV therapy |
| Prophylaxis | 1 mg/kg/day | Until no longer at risk of fungal infection |
Elderly
No dose adjustment is necessary for elderly patients. The pharmacokinetics of micafungin are not significantly affected by age in adults. Clinical studies have included patients up to 94 years of age, and no clinically meaningful differences in safety or efficacy have been observed between older and younger patients. However, elderly patients may be more likely to have concurrent hepatic or renal impairment, which should be monitored during therapy.
Patients with hepatic or renal impairment
No dose adjustment is required for patients with mild to moderate hepatic impairment. Data in patients with severe hepatic impairment are limited, and micafungin should be used with caution in this population. Similarly, no dose adjustment is needed for patients with renal impairment, as micafungin is not significantly eliminated by the kidneys. Micafungin is not dialysable and therefore supplemental dosing after dialysis is not necessary.
Missed dose
Since micafungin is administered in a hospital setting by healthcare professionals, missed doses are unlikely. If a scheduled dose is missed, it should be given as soon as possible. The regular dosing schedule should then resume with the next scheduled dose. A double dose should not be administered to compensate for a missed dose.
Overdose
Limited data are available regarding micafungin overdose. In clinical studies, doses up to 8 mg/kg (maximum total dose 896 mg) have been administered without dose-limiting toxicity. In the event of accidental overdose, general supportive measures should be employed. There is no specific antidote for micafungin. Micafungin is highly protein-bound (over 99%) and is therefore not expected to be removed by haemodialysis.
What Are the Side Effects of Micafungin Hikma?
The most common side effects of micafungin include nausea, vomiting, diarrhoea, elevated liver enzymes, low potassium and magnesium levels, headache, phlebitis at the infusion site, and skin rash. Serious but rare side effects include hepatotoxicity, anaphylaxis, haemolytic anaemia, and Stevens-Johnson syndrome.
Like all medicines, Micafungin Hikma can cause side effects, although not everybody experiences them. The overall safety profile of micafungin is generally favourable, consistent with its selective mechanism of action targeting a fungal-specific pathway. In clinical trials involving over 3,000 patients, the most frequently reported adverse reactions were gastrointestinal disturbances, liver enzyme elevations, and electrolyte imbalances. Most adverse reactions are mild to moderate in severity and reversible upon discontinuation of therapy.
It is important to report any unexpected or persistent symptoms to your healthcare team so that the benefit-risk balance of continued treatment can be reassessed. Your doctor will monitor your blood tests (including liver function, kidney function, and blood counts) regularly during treatment to detect potential adverse effects early.
Very Common
- Hypokalaemia (low potassium levels)
- Hypomagnesaemia (low magnesium levels)
- Hypocalcaemia (low calcium levels)
Common
- Nausea, vomiting, diarrhoea, abdominal pain
- Elevated liver enzymes (ALT, AST, alkaline phosphatase)
- Elevated bilirubin
- Headache
- Phlebitis / thrombophlebitis at infusion site
- Skin rash, pruritus (itching)
- Leukopenia (low white blood cell count)
- Neutropenia
- Anaemia
- Pyrexia (fever)
- Rigors (shivering)
- Tachycardia (fast heart rate)
- Hyponatraemia (low sodium levels)
- Hypophosphataemia (low phosphate levels)
Uncommon
- Hepatitis, hepatic failure, hepatomegaly
- Renal impairment, elevated serum creatinine
- Coagulopathy, disseminated intravascular coagulation
- Haemolytic anaemia, haemoglobinuria
- Anaphylaxis / anaphylactoid reaction
- Urticaria (hives), erythema
- Hypotension, hypertension
- Dyspnoea (difficulty breathing)
- Somnolence (drowsiness), tremor
- Pancytopenia, thrombocytopenia
Rare
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Erythema multiforme
- Hepatic necrosis
- Renal tubular acidosis
- Shock
Contact your healthcare team immediately if you experience: yellowing of the skin or eyes (jaundice), dark urine, severe abdominal pain, unexplained bleeding or bruising, severe skin rash with blistering, difficulty breathing or swelling of the face/throat, or very dark or red-coloured urine. These may indicate serious complications that require urgent medical intervention.
Long-term safety considerations
In preclinical studies, micafungin caused hepatocellular tumours in rats following prolonged administration at doses above the clinical range. The clinical relevance of this finding is uncertain, but it informs the recommendation that micafungin should only be used when the benefits of treatment clearly outweigh the risks. Treatment duration should be kept to the minimum necessary for clinical cure. Your treating physician will take this into consideration when determining the length of your treatment course.
How Should You Store Micafungin Hikma?
Unopened vials of Micafungin Hikma should be stored below 25°C in the original packaging. Do not freeze. After reconstitution, the solution should be used immediately, or may be stored for up to 24 hours at 2–8°C. Do not use this medicine after the expiry date.
Proper storage of Micafungin Hikma is essential to maintain the drug’s potency and sterility. Although storage will primarily be managed by hospital pharmacy staff, understanding the storage requirements is important for ensuring medication quality.
- Unopened vials: Store below 25°C. Keep the vials in the original carton to protect from light. Do not freeze.
- After reconstitution: The reconstituted concentrate should be diluted and used immediately. If not used immediately, the diluted solution may be stored for up to 24 hours at 2–8°C (refrigerated) and must be protected from light.
- Do not use if the solution appears cloudy, discoloured, or contains visible particulate matter. The reconstituted solution should be clear and colourless to slightly yellow.
- Shelf life: The shelf life of unopened vials is 36 months when stored under recommended conditions. Always check the expiry date on the packaging before use.
- Disposal: Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard via household waste.
Micafungin Hikma must be reconstituted using sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection. The reconstituted solution must then be further diluted before intravenous administration. The vial should be swirled gently; do not shake vigorously as this may cause foaming. Only a healthcare professional should prepare and administer this medicine.
What Does Micafungin Hikma Contain?
Each vial of Micafungin Hikma contains 50 mg of micafungin (as micafungin sodium) as the active substance. Excipients include lactose monohydrate, citric acid anhydrous, and sodium hydroxide (for pH adjustment).
Understanding the composition of your medicine is important, particularly if you have known allergies or intolerances to specific excipients. The full qualitative and quantitative composition of Micafungin Hikma is as follows:
Active substance
Each vial contains 50 mg of micafungin (equivalent to 50.64 mg of micafungin sodium). Micafungin sodium is a white to off-white powder with a molecular weight of approximately 1,292.26 g/mol. It is freely soluble in water and dimethyl sulphoxide, and practically insoluble in ethanol.
Excipients
- Lactose monohydrate: Used as a bulking agent and lyoprotectant to maintain the stability of the lyophilised (freeze-dried) powder. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should inform their doctor before receiving this medicine.
- Citric acid anhydrous: Used as a buffering agent to maintain the appropriate pH of the solution after reconstitution.
- Sodium hydroxide: Used for pH adjustment to ensure optimal stability and compatibility with intravenous fluids.
The medicine does not contain any preservatives, antimicrobial agents, or colouring agents. It is free from gluten, peanut, and soy-derived excipients. The lactose content per vial is approximately 200 mg, which is considered negligible from a clinical standpoint for most patients with lactose intolerance, as the medicine is administered intravenously rather than orally.
Frequently Asked Questions About Micafungin Hikma
Micafungin Hikma is an echinocandin antifungal used for three main purposes: treating invasive candidiasis (serious Candida bloodstream infections), treating oesophageal candidiasis, and preventing Candida infections in immunocompromised patients undergoing bone marrow transplantation or with prolonged neutropenia. It is given as an intravenous infusion in hospital settings and is effective against multiple Candida species including those resistant to fluconazole.
Micafungin Hikma is supplied as a powder that must be reconstituted and diluted by a healthcare professional before use. It is administered as a slow intravenous infusion over approximately one hour, once daily. The powder is dissolved in sterile saline or glucose solution, and the resulting clear solution is infused through a peripheral or central intravenous line. It cannot be given orally, intramuscularly, or as a rapid intravenous injection.
The most common side effects include electrolyte disturbances (particularly low potassium, magnesium, and calcium levels), nausea, vomiting, diarrhoea, elevated liver enzymes, headache, phlebitis at the infusion site, and skin rash. Most side effects are mild to moderate and typically resolve after treatment ends. Serious but rare side effects include severe liver damage, allergic reactions, and blood disorders. Your medical team will monitor you with regular blood tests during treatment.
Yes, micafungin is one of the few antifungal agents approved for use across all paediatric age groups, including premature and term neonates. Children weighing less than 40 kg receive weight-based dosing (typically 1–4 mg/kg/day depending on the indication), which provides higher per-kilogram doses than adults to compensate for the faster drug clearance observed in younger patients. Children weighing 40 kg or more receive the same doses as adults.
Micafungin differs from azole antifungals like fluconazole in several key ways. It targets the fungal cell wall (1,3-beta-D-glucan synthesis) rather than the cell membrane (ergosterol synthesis). This gives it activity against Candida species that are resistant to fluconazole, including C. glabrata and C. krusei. It also has significantly fewer drug interactions than azoles because it does not significantly affect cytochrome P450 enzymes. However, micafungin can only be given intravenously, whereas fluconazole is available in both oral and IV formulations.
Micafungin should not be used during pregnancy unless clearly necessary, as animal studies have shown potential harm to the developing foetus. Women of childbearing age should use effective contraception during treatment. Regarding breastfeeding, it is unknown whether micafungin passes into human breast milk (it does in animals), so a decision should be made between discontinuing breastfeeding or discontinuing the drug, considering the importance of treatment to the mother.
References
- European Medicines Agency (EMA). Micafungin – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933
- Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19–37.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842–849.
- Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–1527.
- van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
- Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children. Clin Microbiol Infect. 2012;18 Suppl 7:38–52.
- British National Formulary (BNF). Micafungin. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Mycamine (micafungin sodium) Prescribing Information. Available at: www.fda.gov. Accessed January 2026.
Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed physicians specialising in infectious disease, clinical pharmacology, and hospital medicine.
Medical Review Board
Board-certified infectious disease specialists and clinical pharmacologists who review all drug content according to EMA, FDA, and WHO guidelines.
Evidence Standards
All information is based on peer-reviewed evidence, regulatory-approved prescribing information, and international clinical guidelines. GRADE evidence framework applied.